Cat. No.: HY-B1787

Sulindac sulfone

Customer Review

Based on 1 Customer Validation

Sulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of VDAC1/2 to inhibit the mTORC1 pathway, reduces Cyclin D1 levels, and induces G₁ cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer.

For research use only. We do not sell to patients.

Purity: 98.10%
CAS No.: 59973-80-7
Formula: C₂₀H₁₇FO₄S
Molecular Weight:372.41

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Sulindac sulfone Chemical Structure

CAS No.: 59973-80-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

mTORC1

PPARγ

All mTOR Isoforms :

All CDK Isoforms :

All PPAR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
COLO 320	IC₅₀	>200 μM Compound: b	Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
MIA PaCa-2	IC₅₀	>200 μM Compound: b	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 20801552]

In Vitro

Sulindac sulfone (50-600 μM; 1-6 days) inhibits the proliferation and induces the death of colon cancer cell line Caco-2. After 6 days of treatment, the inhibitory effect on proliferation at concentrations ≥50 μM and the inducing effect on cell death at concentrations ≥150 μM are both statistically significant^[1].
Sulindac sulfone (600 μM; duration leading to 50% reduction in colony formation) upregulates the expression of the SSAT gene by 3.94-fold in the colon cancer cell line Caco-2 at its IC₅₀ concentration^[1].
Sulindac sulfone (10-600 μM; 24-48 h) induces the expression of SSAT mRNA in the colon cancer cell line Caco-2; at the concentration of 600 μM, the expression level increases by 2.23-fold after 24 h of treatment and by 5.58-fold after 48 h of treatment; statistically significant induction is also observed at concentrations ≥100 μM with 48 h of treatment^[1].
Sulindac sulfone (600 μM; 48 h) increases SSAT enzyme activity by 2-fold and reduces intracellular spermine and spermidine levels by 2-fold in human colon cancer Caco-2 cells^[1].
Sulindac sulfone (600 μM; 48 h) activates PPAR response elements and increases luciferase activity by 2-fold in Caco-2 colon cancer cells after 48 h of treatment^[1].
Sulindac sulfone (up to 10 mM) does not inhibit cyclooxygenase (type I) activity^[2].
Sulindac sulfone (1-100 μM) weakly inhibits 5-lipoxygenase activity, with inhibition rates of 10%, 14% and 30% at concentrations of 1 μM, 10 μM and 100 μM, respectively^[2].
Sulindac sulfone (1-100 μM) exerts no significant inhibitory effect on 15-lipoxygenase activity: the inhibition rate is 8% at 1 μM, 0% at 10 μM, while the enzyme activity increases by 15% instead at 100 μM^[2].
Sulindac sulfone (9.4-600 μM; 72 h) inhibits the growth of colon cancer HT-29, DLD-1 and SW480 cells in a dose-dependent manner. A significant reduction in cell viability is observed at concentrations ≥37.5 μM after 72 h of treatment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Colon cancer HT-29, DLD-1, and SW480 cells
Concentration:

9.4, 18.8, 37.5, 75, 150, 300, 600 μM
Incubation Time:

72 h
Result:

Inhibited cell growth in all three cell lines in a dose-dependent manner.
Reduced cell viability to ~10-20% at 600 μM across all cell lines.
Caused statistically significant decreases in cell viability at ≥37.5 μM (HT-29), ≥150 μM (DLD-1), and ≥150 μM (SW480).

Cell Cycle Analysis^[3]

Cell Line:

Colon cancer HT-29, DLD-1, and SW480 cells
Concentration:

75, 150, 300, 600 μM
Incubation Time:

72 h
Result:

Induced G1 phase cell cycle arrest in all three cell lines.
Caused statistically significant increases in G1 phase population at all tested concentrations.
Caused statistically significant decreases in S phase population at 300 and 600 μM across all cell lines.

Western Blot Analysis^[3]

Cell Line:

human colon cancer HT-29, DLD-1, and SW480 cells
Concentration:

600 μM
Incubation Time:

24 h
Result:

Did not reduce the expression levels of VDAC1 or VDAC2 in any of the three cell lines.

In Vivo

Sulindac sulfone (500-2000 ppm; dietary; continuous; 31 weeks) inhibits azoxymethane-induced colon carcinogenesis in male F344 rats in vivo in a dose-dependent manner, with the 2000 ppm dose reducing overall colon neoplasia incidence to 26.7% and total tumor multiplicity to 0.43 tumors/animal, without significantly reducing colonic PGE₂ levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

F344 (male, 6 weeks old at study start, azoxymethane-induced colon cancer model)^[2]
Dosage:

500 ppm; 1000 ppm; 2000 ppm
Administration:

dietary; continuous; 31 weeks
Result:

Achieved mean serum levels of 92 μg/mL (500 ppm), 129 μg/mL (1000 ppm), and 146 μg/mL (2000 ppm), and mean cecal levels of 0.96 mg/mL (500 ppm), 1.24 mg/mL (1000 ppm), and 2.59 mg/mL (2000 ppm), with no metabolic conversion to sulindac or other metabolites detected.
Reduced carcinoma burden to 3.53 cm at 500 ppm (P < 0.05 vs control).
Lowered colon adenoma incidence to 40.0%, carcinoma incidence to 36.7%, and overall neoplasia incidence to 63.3% at 1000 ppm (all P < 0.05 vs control).
Reduced tumor multiplicity to 0.53 adenomas/animal, 0.37 carcinomas/animal, and 0.90 total neoplasia/animal at 1000 ppm (all P < 0.05 vs control).
Lowered tumor burden to 1.50 cm for adenomas, 1.77 cm for carcinomas, and 3.27 cm for total neoplasia at 1000 ppm (all P < 0.05 vs control).
Reduced colon adenoma incidence to 20.0%, carcinoma incidence to 10.0%, and overall neoplasia incidence to 26.7% at 2000 ppm (all P < 0.05 vs control).
Lowered tumor multiplicity to 0.30 adenomas/animal, 0.13 carcinomas/animal, and 0.43 total neoplasia/animal at 2000 ppm (all P < 0.05 vs control).
Reduced tumor burden to 0.70 cm for adenomas, 1.17 cm for carcinomas, and 1.87 cm for total neoplasia at 2000 ppm (all P < 0.05 vs control).
Exhibited a highly significant dose-response relationship for colon tumor incidence (P < 0.0001), multiplicity (P < 0.0001), and burden (P = 0.0001).
Maintained colonic PGE₂ levels at 78-118% of control levels across all doses, with no statistically significant reduction detected in either proximal or distal colon.

Chemical Information

CAS No. 59973-80-7
Appearance Solid
Molecular Weight 372.41
Formula C₂₀H₁₇FO₄S
Color Light yellow to yellow
SMILES

O=C(O)CC(C1=C/2C=CC(F)=C1)=C(C)C2=C\C3=CC=C(S(=O)(C)=O)C=C3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (335.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6852 mL

13.4261 mL

26.8521 mL

5 mM

0.5370 mL

2.6852 mL

5.3704 mL

10 mM

0.2685 mL

1.3426 mL

2.6852 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Babbar N, et al. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003;278(48):47762-47775. [Content Brief]

[2]. Piazza GA, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997 Jul 15;57(14):2909-15. [Content Brief]

[3]. Aono Y, et al. Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2. Biochem Biophys Res Commun. 2018;505(4):1203-1210. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6852 mL	13.4261 mL	26.8521 mL	67.1303 mL
	5 mM	0.5370 mL	2.6852 mL	5.3704 mL	13.4261 mL
	10 mM	0.2685 mL	1.3426 mL	2.6852 mL	6.7130 mL
	15 mM	0.1790 mL	0.8951 mL	1.7901 mL	4.4754 mL
	20 mM	0.1343 mL	0.6713 mL	1.3426 mL	3.3565 mL
	25 mM	0.1074 mL	0.5370 mL	1.0741 mL	2.6852 mL
	30 mM	0.0895 mL	0.4475 mL	0.8951 mL	2.2377 mL
	40 mM	0.0671 mL	0.3357 mL	0.6713 mL	1.6783 mL
	50 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3426 mL
	60 mM	0.0448 mL	0.2238 mL	0.4475 mL	1.1188 mL
	80 mM	0.0336 mL	0.1678 mL	0.3357 mL	0.8391 mL
	100 mM	0.0269 mL	0.1343 mL	0.2685 mL	0.6713 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sulindac sulfone

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Drug Metabolite Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

All mTOR Isoforms

All CDK Isoforms

All PPAR Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Sulindac sulfone Related Classifications

Cat. No.: HY-B1787